Sun Biomedical Ltd.

by Mary Thompson "Where do we go from here" is a question that physicians and manufacturers active in the interventional cardiology space have asked, and successfully answered, time and again over the

Safety concerns and a cut back in usage have dimmed the luster of the drug-eluting stents, but Xtent believes it has the technology to make the drug-eluting stent market explode again. by David Cassak

While most companies are developing new ways to deliver drugs off of stents, OrbusNeich is looking to capture circulating endothelial progenitor cells onto its device to promote healing naturally, wit

When one first meets Bruce Roberts and Hideki Mitani, managing directors of their eponymous global private equity and financial/strategic advisory firm based in New York and Tokyo, neither strikes you